Oriol Sibila1,2, Laia Garcia-Bellmunt1,2, Jordi Giner1,2, Ana Rodrigo-Troyano1,2, Guillermo Suarez-Cuartin1,2, Alfons Torrego1,2, Diego Castillo1,2, Ingrid Solanes1,2, Eder F Mateus2,3, Silvia Vidal2,3, Ferran Sanchez-Reus2,4, Ernest Sala5,6, Borja G Cosio5,6, Marcos I Restrepo7, Antonio Anzueto7, James D Chalmers8, Vicente Plaza1,2. 1. 1 Servei de Pneumologia, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. 2. 2 Institut d'Investigació Biomèdica Sant Pau, Barcelona, Spain. 3. 3 Laboratori d'Immunologia Experimental, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. 4. 4 Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau, Universitat Autònomoa de Barcelona, Barcelona, Spain. 5. 5 Servei de Pneumologia, Hospital Son Espases-Instituto de Investigación Sanitaria de Palma, Palma de Mallorca, Spain. 6. 6 Ciber de Enfermedades Respiratorias, Madrid, Spain. 7. 7 South Texas Veterans Health Care System and University of Texas Health Science Center at San Antonio, San Antonio, Texas; and. 8. 8 Tayside Respiratory Research Group, University of Dundee, Dundee, United Kingdom.
Abstract
RATIONALE: Mucins are essential for airway defense against bacteria. We hypothesized that abnormal secreted airway mucin levels would be associated with bacterial colonization in patients with severe chronic obstructive pulmonary disease (COPD) Objectives: To investigate the relationship between mucin levels and the presence of potentially pathogenic micro-organisms in the airways of stable patients with severe COPD Methods: Clinically stable patients with severe COPD were examined prospectively. All patients underwent a computerized tomography scan, lung function tests, induced sputum collection, and bronchoscopy with bronchoalveolar lavage (BAL) and protected specimen brush. Patients with bronchiectasis were excluded. Secreted mucins (MUC2, MUC5AC, and MUC5B) and inflammatory markers were assessed in BAL and sputum by ELISA. MEASUREMENTS AND MAIN RESULTS: We enrolled 45 patients, with mean age (±SD) of 67 (±8) years and mean FEV1 of 41 (±10) % predicted. A total of 31% (n = 14) of patients had potentially pathogenic micro-organisms in quantitative bacterial cultures of samples obtained by protected specimen brush. Patients with COPD with positive cultures had lower levels of MUC2 both in BAL (P = 0.02) and in sputum (P = 0.01). No differences in MUC5B or MUC5AC levels were observed among the groups. Lower MUC2 levels were correlated with lower FEV1 (r = 0.32, P = 0.04) and higher sputum IL-6 (r = -0.40, P = 0.01). CONCLUSIONS: Airway MUC2 levels are decreased in patients with severe COPD colonized by potentially pathogenic micro-organisms. These findings may indicate one of the mechanisms underlying airway colonization in patients with severe COPD. Clinical trial registered with www.clinicaltrials.gov (NCT01976117).
RATIONALE: Mucins are essential for airway defense against bacteria. We hypothesized that abnormal secreted airway mucin levels would be associated with bacterial colonization in patients with severe chronic obstructive pulmonary disease (COPD) Objectives: To investigate the relationship between mucin levels and the presence of potentially pathogenic micro-organisms in the airways of stable patients with severe COPD Methods: Clinically stable patients with severe COPD were examined prospectively. All patients underwent a computerized tomography scan, lung function tests, induced sputum collection, and bronchoscopy with bronchoalveolar lavage (BAL) and protected specimen brush. Patients with bronchiectasis were excluded. Secreted mucins (MUC2, MUC5AC, and MUC5B) and inflammatory markers were assessed in BAL and sputum by ELISA. MEASUREMENTS AND MAIN RESULTS: We enrolled 45 patients, with mean age (±SD) of 67 (±8) years and mean FEV1 of 41 (±10) % predicted. A total of 31% (n = 14) of patients had potentially pathogenic micro-organisms in quantitative bacterial cultures of samples obtained by protected specimen brush. Patients with COPD with positive cultures had lower levels of MUC2 both in BAL (P = 0.02) and in sputum (P = 0.01). No differences in MUC5B or MUC5AC levels were observed among the groups. Lower MUC2 levels were correlated with lower FEV1 (r = 0.32, P = 0.04) and higher sputum IL-6 (r = -0.40, P = 0.01). CONCLUSIONS: Airway MUC2 levels are decreased in patients with severe COPD colonized by potentially pathogenic micro-organisms. These findings may indicate one of the mechanisms underlying airway colonization in patients with severe COPD. Clinical trial registered with www.clinicaltrials.gov (NCT01976117).
Authors: Oriol Sibila; Guillermo Suarez-Cuartin; Ana Rodrigo-Troyano; Thomas C Fardon; Simon Finch; Eder Freddy Mateus; Laia Garcia-Bellmunt; Diego Castillo; Silvia Vidal; Ferran Sanchez-Reus; Marcos I Restrepo; James D Chalmers Journal: Respirology Date: 2015-07-14 Impact factor: 6.424
Authors: Gaetano Caramori; Paolo Casolari; Carmela Di Gregorio; Marina Saetta; Simonetta Baraldo; Piera Boschetto; Kazuhiro Ito; Leonardo M Fabbri; Peter J Barnes; Ian M Adcock; Giorgio Cavallesco; Kian F Chung; Alberto Papi Journal: Histopathology Date: 2009-09 Impact factor: 5.087
Authors: Markus O Henke; Armin Renner; Rudolf M Huber; Michael C Seeds; Bruce K Rubin Journal: Am J Respir Cell Mol Biol Date: 2004-02-26 Impact factor: 6.914
Authors: Gavin C Donaldson; Terence A R Seemungal; Irem S Patel; Angshu Bhowmik; Tom M A Wilkinson; John R Hurst; Peter K Maccallum; Jadwiga A Wedzicha Journal: Chest Date: 2005-10 Impact factor: 9.410
Authors: Yijun Qi; Jo Lohman; Kaitlin M Bratlie; Nathan Peroutka-Bigus; Bryan Bellaire; Michael Wannemuehler; Kyoung-Jin Yoon; Terrence A Barrett; Qun Wang Journal: J Biomed Mater Res A Date: 2019-05-23 Impact factor: 4.396
Authors: Aran Singanayagam; Joseph Footitt; Matthias Marczynski; Giorgia Radicioni; Michael T Cross; Lydia J Finney; Maria-Belen Trujillo-Torralbo; Maria Calderazzo; Jie Zhu; Julia Aniscenko; Thomas B Clarke; Philip L Molyneaux; Nathan W Bartlett; Miriam F Moffatt; William O Cookson; Jadwiga Wedzicha; Christopher M Evans; Richard C Boucher; Mehmet Kesimer; Oliver Lieleg; Patrick Mallia; Sebastian L Johnston Journal: J Clin Invest Date: 2022-04-15 Impact factor: 19.456